| Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future opportunities, and … KS Taskar, V Pilla Reddy, H Burt, MM Posada, M Varma, M Zheng, ... Clinical Pharmacology & Therapeutics 107 (5), 1082-1115, 2020 | 105 | 2020 |
| Physiologically-based toxicokinetic modeling of zearalenone and its metabolites: application to the Jersey girl study D Mukherjee, SG Royce, JA Alexander, B Buckley, SS Isukapalli, ... PLoS One 9 (12), e113632, 2014 | 54 | 2014 |
| Modeling population exposures to silver nanoparticles present in consumer products SG Royce, D Mukherjee, T Cai, SS Xu, JA Alexander, Z Mi, L Calderon, ... Journal of Nanoparticle Research 16, 1-25, 2014 | 40 | 2014 |
| Clinical implications of altered drug transporter abundance/function and PBPK modeling in specific populations: an ITC perspective X Chu, B Prasad, S Neuhoff, K Yoshida, JS Leeder, D Mukherjee, ... Clinical Pharmacology & Therapeutics 112 (3), 501-526, 2022 | 34 | 2022 |
| Modeling physicochemical interactions affecting in vitro cellular dosimetry of engineered nanomaterials: application to nanosilver D Mukherjee, BF Leo, SG Royce, AE Porter, MP Ryan, S Schwander, ... Journal of nanoparticle research 16, 1-16, 2014 | 27 | 2014 |
| Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach S Bhatnagar, D Mukherjee, AH Salem, D Miles, RM Menon, JP Gibbs Cancer Chemotherapy and Pharmacology, 1-10, 2021 | 25 | 2021 |
| Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model D Mukherjee, J Zha, RM Menon, M Shebley Journal of pharmacokinetics and pharmacodynamics 45, 443-456, 2018 | 21 | 2018 |
| Current practices, gap analysis, and proposed workflows for PBPK modeling of cytochrome P450 induction: an industry perspective N Hariparsad, D Ramsden, K Taskar, J Badée, K Venkatakrishnan, ... Clinical Pharmacology & Therapeutics 112 (4), 770-781, 2022 | 20 | 2022 |
| Modeling In Vitro Cellular Responses to Silver Nanoparticles D Mukherjee, SG Royce, S Sarkar, A Thorley, S Schwander, MP Ryan, ... Journal of Toxicology 2014 (1), 852890, 2014 | 19 | 2014 |
| Computational multiscale toxicodynamic modeling of silver and carbon nanoparticle effects on mouse lung function D Mukherjee, D Botelho, AJ Gow, J Zhang, PG Georgopoulos PLoS One 8 (12), e80917, 2013 | 17 | 2013 |
| In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities JO Njoku, D Amaral Silva, D Mukherjee, GK Webster, R Löbenberg AAPS PharmSciTech 20, 1-10, 2019 | 8 | 2019 |
| Modeling In Vivo Interactions of Engineered Nanoparticles in the Pulmonary Alveolar Lining Fluid D Mukherjee, A Porter, M Ryan, S Schwander, KF Chung, T Tetley, ... Nanomaterials 5 (3), 1223-1249, 2015 | 7 | 2015 |
| Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure D Mukherjee, MS Chiney, X Shao, TR Ju, M Shebley, P Marroum Biopharmaceutics & Drug Disposition 43 (3), 98-107, 2022 | 6 | 2022 |
| Impact of multiple concomitant CYP3A inhibitors on Venetoclax pharmacokinetics: a PBPK and population PK‐informed analysis D Mukherjee, DJ Brackman, AA Suleiman, J Zha, RM Menon, AH Salem The Journal of Clinical Pharmacology 63 (1), 119-125, 2023 | 5 | 2023 |
| Virtual bioequivalence assessment of elagolix formulations using physiologically based pharmacokinetic modeling D Mukherjee, MJ Chen, X Shao, TR Ju, M Shebley, P Marroum The AAPS Journal 25 (3), 30, 2023 | 3 | 2023 |
| PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF GLECAPREVIR AND PIBRENTASVIR AS A COMBINATION: MECHANISTIC MODELING OF NON-LINEAR PHARMACOKINETICS. D Mukherjee, M Kosloski, W Liu, M Shebley CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S81-S81, 2018 | 3 | 2018 |
| Computational modeling of nanoparticle distribution and toxicity in biological systems D Mukherjee Rutgers The State University of New Jersey, School of Graduate Studies, 2015 | 3 | 2015 |
| Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based … D Mukherjee, M Collins, DE Dylla, J Kaur, D Semizarov, A Martinez, ... Infectious Diseases and Therapy 12 (8), 2057-2070, 2023 | 2 | 2023 |
| Amorphous solid dispersions in early stage of formulation development: predicting excipient influence on dissolution profiles using DDDPlus JO Njoku, D Mukherjee, GK Webster, R Löbenberg Cellulose 586 (67.87), 19.0, 2020 | 1 | 2020 |
| Physiologically‐based Pharmacokinetic Model Development and Simulations to Evaluate Potential Drug‐Drug Interaction of Veliparib HX D Mukherjee, S Nuthalapati, C Biesdorf, RA Carr, JP Gibbs, M Shebley Clinical Pharmacology in Drug Development 9 (S2), 1-75, 2020 | | 2020 |
Kian Fan ChungImperial College London在 imperial.ac.uk 的电子邮件经过验证
